Cargando…
MON-LB101 Pharmacokinetics of Liothyronine during Thyroid Hormone Therapy Withdrawal
Background Liothyronine (LT3) is a substitute for levothyroxine (LT4) for thyroid cancer patients during the preparation for nuclear medicine procedures, and there is renewed interest in its use in combination with LT4 in patients who do not respond to the standard treatment. This therapy is commonl...
Autores principales: | Celi, Francesco, Wohlford, George, Linderman, Joyce, Smith, Sheila, Yavuz, Sahzene, Pucino, Frank, Van Tassell, Benjamin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550962/ http://dx.doi.org/10.1210/js.2019-MON-LB101 |
Ejemplares similares
-
Acute Effects of Liothyronine Administration on Cardiovascular System and Energy Metabolism in Healthy Volunteers
por: Chen, Shanshan, et al.
Publicado: (2022) -
MON-LB87 Recombinant Human TSH vs Thyroid Hormone Withdrawal Preparation for Radioiodine Ablation in Pediatric Differentiated Thyroid Cancer
por: Schumm, Max A, et al.
Publicado: (2020) -
SAT-519 Armour Thyroid and Liothyronine Combination Potentiated Thrombosis
por: Shin, Tai Ho, et al.
Publicado: (2020) -
MON-LB75 Stratifying the Risk of Malignancy in Indeterminate Thyroid Nodules
por: Imam, Shahnawaz, et al.
Publicado: (2020) -
MON-LB095 Thyroid Nodule Localization as a Predictor Factor for Malignancy
por: Sibai, Zakaria, et al.
Publicado: (2019)